Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Parthenon Therapeutics has raised $65.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.
Parthenon Therapeutics's investors include Breakout Ventures, S32, Pfizer Venture Investments, Alexandria Venture Investments, KdT Ventures.
Parthenon Therapeutics is headquartered in Cambridge, United States.
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Parthenon Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Parthenon Therapeutics — Funding & Investors." VCBacked, November 3, 2021, https://www.vcbacked.co/company/parthenon-therapeutics. Accessed November 13, 2026.
VCBacked. (2021). Parthenon Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/parthenon-therapeutics
{{cite web |title=Parthenon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/parthenon-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Parthenon Therapeutics? Request a listing update